Toggle Main Menu Toggle Search

Open Access padlockePrints

Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia: Reduction in nocturnal hypoglycemia in those at greatest risk

Lookup NU author(s): Professor James Shaw


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Objective: To evaluate a sensor-augmented insulin pump with a low glucose suspend (LGS) feature that automatically suspends basal insulin delivery for up to 2 h in response to sensor-detected hypoglycemia. Research Design and Methods: The LGS feature of the Paradigm Veo insulin pump (Medtronic, Inc., Northridge, CA) was tested for 3 weeks in 31 adults with type 1 diabetes. RESULTS-There were 166 episodes of LGS: 66% of daytime LGS episodes were terminated within 10 min, and 20 episodes lasted the maximum 2 h. LGS use was associated with reduced nocturnal duration <= 2.2 mmol/L in those in the highest quartile of nocturnal hypoglycemia at baseline (median 46.2 vs. 1.8 min/day, P = 0.02 [LGS-OFF vs. LGS-ON]). Median sensor glucose was 3.9 mmol/L after 2-h LGS and 8.2 mmol/L at 2 h after basal restart. CONCLUSIONS-Use of an insulin pump with LGS was associated with reduced nocturnal hypoglycemia in those at greatest risk and was well accepted by patients.

Publication metadata

Author(s): Choudhary P, Shin J, Wang YY, Evans ML, Hammond PJ, Kerr D, Shaw JAM, Pickup JC, Amiel SA

Publication type: Article

Publication status: Published

Journal: Diabetes Care

Year: 2011

Volume: 34

Issue: 9

Pages: 2023-2025

Print publication date: 01/09/2011

ISSN (print): 0149-5992

ISSN (electronic): 1935-5548

Publisher: American Diabetes Association


DOI: 10.2337/dc10-2411


Altmetrics provided by Altmetric